Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
3 minute read
  • Biotech
  • General

Sheba Medical Center and Enlivex Announce Dosing Of The First Patient In Phase I/II Trial Evaluating Allocetra Combined With Chemotherapy In Patients With Peritoneal Metastases Arising From Solid Cancers

By Bill Haddad
July 6, 8:37 AM
First clinical trial of Allocetra™ in patients with cancer builds upon promising preclinical studies demonstrating its broadly applicable immunotherapeutic effects in solid tumor models Sheba Medical Center was

ENLV

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • News

Applied Molecular Transport Announces Top-line Phase 2 Results From MARKET Combination Trial Of Oral AMT-101 In Patients With Moderate-to-Severe Ulcerative Colitis

By Benzinga Newsdesk
July 6, 8:05 AM
– Similar clinical remission rates observed of 31.8% (7/22) in patients receiving combination (AMT-101 and adalimumab) versus 33.3% (9/27) in patients receiving placebo plus adalimumab at week

AMTI

Read More
3 minute read
  • Biotech
  • General

Caladrius Biosciences And Cend Therapeutics Highlights Publication Of Pancreatic Cancer Trial Data In The Lancet Gastroenterology And Hepatology

By Bill Haddad
July 6, 8:03 AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, and Cend

CLBS

Read More
3 minute read
  • Biotech
  • FDA
  • General
  • News

Vera Therapeutics Completes Patient Enrollment In Phase 2b ORIGIN Clinical Trial Of Atacicept For The Treatment of IgA Nephropathy

By Bill Haddad
July 6, 7:31 AM
Vera Therapeutics, Inc. (NASDAQ:VERA), a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological disease, today announced completion of

VERA

Read More
1 minute read
  • General
  • M&A
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Why Resolute Forest Products Shares Are Rallying Today?

By Vandana Singh
July 6, 7:29 AM
Through its wholly-owned subsidiary Domtar Corporation, the Paper Excellence Group has agreed to acquire Resolute Forest Products Inc (NYSE:RFP). Fairfax Financial Holdings Limited,…

RFP

Read More
1 minute read
  • General
  • Media
  • News

Ben & Jerry’s Sues Parent Unilever On Israeli business Sale: CNBC

By Shivani Kumaresan
July 6, 7:29 AM
Unilever Plc (NYSE:UL) owned Ben & Jerry’s has sued its owner to stop the sale of its Israeli business to…

UL

Read More
1 minute read
  • FDA
  • General
  • Health Care
  • News

FDA Temporarily Suspends Banning Order On Juul’s E-Cigarettes

By Vandana Singh
July 6, 7:13 AM
The FDA temporarily suspended its ban on sales of the popular e-cigarette maker Juul, backed by Altria Group Inc

MO

Read More
2 minute read
  • General
  • News
  • Social Media

Elon Musk Confesses To A ‘Penchant’ For This Piece Of Clothing

By Shivdeep Dhaliwal
July 6, 7:11 AM
Tesla Inc (NASDAQ: TSLA) CEO Elon Musk confessed his penchant for “creative socks” — something that sets him apart from Dogecoin (CRYPTO: DOGE) co-creator Billy Markus.<

$DOGE

Read More
1 minute read
  • General

Flemish Government And 3M Belgium Announce Plans For 3M Belgium To Invest €571M To ‘benefit the People of Flanders and also carry out certain previously agreed-upon PFAS-related remedial actions.’

By Bill Haddad
July 6, 6:47 AM
ST. PAUL, Minn., July 6, 2022 /PRNewswire/ -- Today, the Flemish Government and 3M Belgium announced plans for 3M Belgium to invest a total of more than €571 million to

MMM

Read More
2 minute read
  • General

Guardant Health And Adicon Announce Partnership To Offer Genomic Profiling Tests To Accelerate Development Of New Cancer Therapies In China

By Bill Haddad
July 6, 6:15 AM
Collaboration will provide biopharmaceutical companies access to Guardant Health's broad portfolio of cancer tests to help advance drug development programs and their clinical trials SINGAPORE, July 6,

GH

Posts pagination

Previous 1 … 2,359 2,360 2,361 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service